Medifast to announce Q2 FY26 results on August 3
Medifast will announce financial results for the quarter ended June 30, 2026, on August 3, 2026, after market close. A conference call will follow at 4:30 p.m. ET, featuring CEO Nick Johnson and CFO Jim Maloney. The webcast will be archived until November 3, 2026.

*this image is generated using AI for illustrative purposes only.
Medifast, the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, will announce financial results for the quarter ended June 30, 2026, on Monday, August 3, 2026, after market close. The announcement will provide insights into the company's performance for the second quarter of FY26. A conference call is scheduled to discuss the results, with additional comments and details from leadership.
Conference Call Details
The conference call will begin at 4:30 p.m. ET on August 3, 2026. Company participants will include Nick Johnson, Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The call will be broadcast live over the Internet and hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com . Alternatively, listeners can access the webcast directly at https://viavid.webcasts.com/starthere.jsp?ei=1768081&tp_key=644d7ae69f .
To join via telephone, listeners may dial (201) 389-0879. The webcast will be archived online and available through November 3, 2026. A telephonic playback will be available from 8:30 p.m. ET on August 3, 2026, through August 10, 2026. Participants can dial (412) 317-6671 and enter access code 13761321 to hear the playback.
About Medifast
Medifast (NYSE: MED) is a metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy. The company's holistic approach integrates science-backed plans and products, personal 1:1 coaching, a supportive community, and behavioral science support to develop healthy habits. Medifast has introduced Metabolic Synchronization®, a breakthrough science targeting metabolic dysfunction through a comprehensive system focused on fat loss, lean mass preservation, and long-term health. Backed by more than 45 years of clinical heritage, Medifast continues to advance its mission of lifelong transformation through metabolic science and human connection.
How will Medifast's Q2 2026 performance reflect the market adoption of its new Metabolic Synchronization® technology?
What strategic initiatives will leadership highlight to drive growth in the second half of FY26?
How might the results impact investor sentiment regarding Medifast's competitive position in the metabolic health sector?

























